编辑精选——瑞士复杂腹主动脉瘤修复的围手术期死亡率与并发症:瑞士血管登记报告
该回顾性队列研究基于瑞士国家血管外科登记库Swissvasc数据,纳入2019年1月1日至2022年12月31日治疗的461例无症状真性非感染性复杂腹主动脉瘤患者,其中333例接受开放动脉瘤修复(OAR),128例接受开窗或分支型腔内主动脉修复(F/B-EVAR)。经倾向评分加权后,两组30天死亡率与并发症率相当,但缺乏集中化治疗,低容量医院中存在死亡率升高的离群值。
要点
- OAR组30天死亡率为3.3%,F/B-EVAR组为3.1%,两组差异无统计学意义(p = .76)。
- F/B-EVAR组需透析的肾衰竭发生率5.5%,高于OAR组的1.5%(p = .024)。
- 作者认为在专科高容量中心治疗并减少围手术期肾损伤和肠系膜缺血,有望降低择期复杂腹主动脉瘤治疗的并发症率和死亡率。
核心结论
- 在瑞士,OAR与F/B-EVAR治疗复杂腹主动脉瘤的30天死亡率和并发症率相当;同时凸显了缺乏集中化治疗的问题。
- 导致死亡的器官特异性并发症为肾衰竭、肠缺血和肢体缺血,尤其在F/B-EVAR后。
研究设计与样本
- 回顾性队列研究,使用瑞士国家血管外科登记库Swissvasc数据,纳入2019年1月1日至2022年12月31日治疗的患者。
- 共识别461例无症状、真性、非感染性复杂腹主动脉瘤患者,其中333例接受OAR,128例接受F/B-EVAR。
- 主要结局为采用Clavien-Dindo分类报告的30天死亡率和并发症率,经倾向评分加权后比较OAR与F/B-EVAR。
主要发现
- 30天总死亡率:OAR组3.3% vs F/B-EVAR组3.1%(p = .76)。
- 倾向评分加权分析显示两种方法并发症率相似:F/B-EVAR(OR 0.69,95% CI 0.45 - 1.05,p = .055)。
- 肠缺血发生率:OAR组1.8% vs F/B-EVAR组3.1%(p = .47)。
- 需透析的肾衰竭发生率:OAR组1.5% vs F/B-EVAR组5.5%(p = .024)。
- F/B-EVAR后高并发症率的治疗特异性并发症包括腹腔间隔室综合征和下肢骨筋膜室综合征。
关键数值与推荐
- 30天死亡率:OAR组3.3% vs F/B-EVAR组3.1%(p = .76)。
- 倾向评分加权并发症率:F/B-EVAR vs OAR的OR 0.69(95% CI 0.45 - 1.05,p = .055)。
- 肠缺血:OAR组1.8% vs F/B-EVAR组3.1%(p = .47)。
- 需透析的肾衰竭:OAR组1.5% vs F/B-EVAR组5.5%(p = .024)。
临床怎么用
- 作者认为,在专科高容量中心治疗,同时努力减少围手术期肾损伤和肠系膜缺血,有望降低择期复杂腹主动脉瘤治疗的并发症率和死亡率。
- 瑞士大多数治疗复杂腹主动脉瘤的医院总体治疗容量低;低容量医院中识别出死亡率升高的离群值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Complex abdominal aortic aneurysms (cAAA) pose a clinical challenge. The aim of this study was to assess the 30 day mortality and morbidity rates for open aneurysm repair (OAR) and fenestrated or branched endovascular aortic repair (F/B-EVAR), and the effect of hospital volume in patients with asymptomatic cAAA in Switzerland. METHODS: Retrospective, cohort study using data from Switzerland's national registry for vascular surgery, Swissvasc, including patients treated from 1 January 2019 to 31 December 2022. All patients with asymptomatic, true, non-infected cAAA were identified. The primary outcome was 30 day mortality and morbidity rates reported using the Clavien-Dindo classification. Outcomes were compared between OAR and F/B-EVAR after propensity score weighting. RESULTS: Of the 461 patients identified, 333 underwent OAR and 128 underwent F/B-EVAR for cAAA. At 30 days, the overall mortality rate was 3.3% after OAR and 3.1% after F/B-EVAR (p = .76). Propensity score weighted analysis indicated similar morbidity rates for both approaches: F/B-EVAR (OR 0.69, 95% CI 0.45 - 1.05, p = .055); intestinal ischaemia (1.8% after OAR, 3.1% after F/B-EVAR, p = .47) and renal failure requiring dialysis (1.5% after OAR, 5.5% after F/B-EVAR, p = .024) were associated with highest morbidity and mortality rates. Treatment specific complications with high morbidity were abdominal compartment syndrome and lower limb compartment syndrome following F/B-EVAR. Overall treatment volume was low for most of the hospitals treating cAAA in Switzerland; outliers with increased mortality rates were identified among low volume hospitals. CONCLUSION: Comparable 30 day mortality and morbidity rates were found between OAR and F/B-EVAR for cAAA in Switzerland; lack of centralisation was also highlighted. Organ specific complications driving death were renal failure, intestinal ischaemia, and limb ischaemia, specifically after F/B-EVAR. Treatment in specialised high volume centres, alongside efforts to reduce peri-procedural kidney injury and mesenteric ischaemia, offers potential to lower morbidity and mortality rates in elective cAAA treatment.
引用
- Meuli L, Kaufmann YL, Lattmann T, et al. Editor's Choice - Peri-operative Mortality and Morbidity of Complex Abdominal Aortic Aneurysm Repair in Switzerland: A Swissvasc Report. Eur J Vasc Endovasc Surg. 2024. PMID: 38906370. doi:10.1016/j.ejvs.2024.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。